Yadav, Vijay K and Balaji, Santhanam and Suresh, Padmanaban S and Liu, X Sherry and Lu, Xin and Li, Zhishan and Guo, X Edward and Mann, J John and Balapure, Anil K and Gershon, Michael D and Medhamurthy, Rudraiah and Vidal, Marc and Karsenty, Gerard and Ducy, Patricia (2010) Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. In: Nature Medicine, 16 (3). 308-U103.
nm.2098.pdf - Published Version
Restricted to Registered users only
Download (616Kb) | Request a copy
Osteoporosis is a disease of low bone mass most often caused by an increase in bone resorption that is not sufficiently compensated for by a corresponding increase in bone formation(1). As gut-derived serotonin (GDS) inhibits bone formation(2), we asked whether hampering its biosynthesis could treat osteoporosis through an anabolic mechanism (that is, by increasing bone formation). We synthesized and used LP533401, a small molecule inhibitor of tryptophan hydroxylase-1 (Tph-1), the initial enzyme in GDS biosynthesis. Oral administration of this small molecule once daily for up to six weeks acts prophylactically or therapeutically, in a dose-dependent manner, to treat osteoporosis in ovariectomized rodents because of an isolated increase in bone formation. These results provide a proof of principle that inhibiting GDS biosynthesis could become a new anabolic treatment for osteoporosis.
|Item Type:||Journal Article|
|Additional Information:||Copyright of this article belongs to Nature Publishing Group.|
|Department/Centre:||Division of Biological Sciences > Molecular Reproduction, Development & Genetics (formed by the merger of DBGL and CRBME)|
|Date Deposited:||23 Mar 2010 12:10|
|Last Modified:||16 Jan 2013 11:45|
Actions (login required)